Ruth Coll

InstitutionBanc de Sang i Teixits (BST)
AddressBarcelona
Spain
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 1 Covid-19 publications, with a maximum of 1 publications in January 2021
    All Publications
    Bar chart showing 7 publications over 5 distinct years, with a maximum of 2 publications in 2012 and 2013
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Garcia-Lopez J, Delgadillo J, Vilarrodona A, Querol S, Ovejo J, Coll R, Millan A, Madrigal A, Soria G, Vidal F, Vives J, Herrero MJ, Lopez I, Sauleda S, Contreras E, Grifols JR, Guasch R, Tahull E, Puig L, Masip A, Argelagués E, Muñiz-Diaz E. SARS-CoV-2/COVID-19 pandemic: first wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfus. 2021 03; 19(2):158-167. PMID: 33539280.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    2. Prat S, Gallardo-Villares S, Vives M, Carreño A, Caminal M, Oliver-Vila I, Chaverri D, Blanco M, Codinach M, Huguet P, Ramírez J, Pinto JA, Aguirre M, Coll R, Garcia-López J, Granell-Escobar F, Vives J. Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis. J Tissue Eng Regen Med. 2018 01; 12(1):e532-e540. PMID: 27684058.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    3. Soler R, Orozco L, Munar A, Huguet M, López R, Vives J, Coll R, Codinach M, Garcia-Lopez J. Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration. Knee. 2016 Aug; 23(4):647-54. PMID: 26783191.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    4. Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian JJ, Coll R, Smith J, Abhyankar B, Birgegård G. Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica. 2014 Apr; 99(4):679-87. PMID: 24334294.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    5. Kiladjian JJ, Besses C, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Birgegård G. Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Clin Drug Investig. 2013 Jan; 33(1):55-63. PMID: 23184668.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    6. Besses C, Kiladjian JJ, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Abhyankar B, Birgegård G. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leuk Res. 2013 Feb; 37(2):162-8. PMID: 23199894.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    7. Besses C, Zeller W, Alvarez-Larrán A, Coll R, Troy S, Purkayastha J, Martin P, Freitag C. Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (= 65 years) patients with essential thrombocythemia. Int J Clin Pharmacol Ther. 2012 Nov; 50(11):787-96. PMID: 22943924.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials